The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Illumina (NASDAQ:ILMN) and the rest of the life sciences tools & services stocks fared in Q4.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Agilent (NYSE:A) and its peers.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers.
Let’s dig into the relative performance of Mettler-Toledo (NYSE:MTD) and its peers as we unravel the now-completed Q4 research tools & consumables earnings season.
Shareholders of Bruker would probably like to forget the past six months even happened. The stock has dropped 39.9% and now trades at a new 52-week low of $41.52. This may have investors wondering how to approach the situation.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Bruker (NASDAQ:BRKR) and its peers.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Danaher (NYSE:DHR) and the best and worst performers in the research tools & consumables industry.
Scientific instrument company Bruker (NASDAQ:BRKR). reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 14.6% year on year to $979.6 million. On the other hand, the company’s full-year revenue guidance of $3.51 billion at the midpoint came in 1.8% below analysts’ estimates. Its non-GAAP profit of $0.76 per share was 3.2% above analysts’ consensus estimates.
